Arkadios Wealth Advisors Sells 1,358 Shares of Novo Nordisk A/S (NYSE:NVO)

Arkadios Wealth Advisors reduced its position in Novo Nordisk A/S (NYSE:NVO) by 7.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,404 shares of the company’s stock after selling 1,358 shares during the period. Arkadios Wealth Advisors’ holdings in Novo Nordisk A/S were worth $1,497,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of NVO. Natixis Advisors LLC increased its position in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC grew its stake in Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after buying an additional 19,870 shares during the last quarter. Talbot Financial LLC acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $4,066,000. Versant Capital Management Inc purchased a new stake in Novo Nordisk A/S in the fourth quarter valued at about $86,000. Finally, Zions Bancorporation N.A. grew its stake in shares of Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 5.2 %

Novo Nordisk A/S stock opened at $78.74 on Monday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market cap of $353.33 billion, a PE ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45. The stock’s 50 day simple moving average is $97.76 and its two-hundred day simple moving average is $117.05. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NVO. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.